Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation
Article first published online: 26 AUG 2005
Alimentary Pharmacology & Therapeutics
Volume 22, Issue 5, pages 373–380, September 2005
How to Cite
REILLY, M. C., BARGHOUT, V., MCBURNEY, C. R. and NIECKO, T. E. (2005), Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics, 22: 373–380. doi: 10.1111/j.1365-2036.2005.02577.x
- Issue published online: 26 AUG 2005
- Article first published online: 26 AUG 2005
- Accepted for publication 19 June 2005
Background : Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation.
Aim : To assess tegaserod's effect on work productivity and daily activity.
Methods : Women, 18–65 years old and meeting Rome II criteria for irritable bowel syndrome with constipation, were randomized to a double-blind, placebo-controlled, multicentre study of tegaserod 6 mg b.d. or placebo. Productivity loss and daily activity impairment because of irritable bowel syndrome were measured with the Work Productivity and Activity Impairment questionnaire for irritable bowel syndrome, modified to exclude diarrhoea as a symptom. Assessments were made at baseline, weeks 2 and 4.
Results : A total of 2660 women were randomized and, of these, 1675 [tegaserod (n = 1363), placebo (n = 312)] were employed and completed Work Productivity and Activity Impairment for irritable bowel syndrome questionnaires. Compared with placebo, tegaserod significantly reduced work and daily activity impairment at weeks 2 and 4. Tegaserod reduced absenteeism by 2.6% (P = 0.004), presenteeism by 5.4% (P < 0.0001), overall work productivity loss by 6.3% (P < 0.0001), and activity impairment by 5.8% (P < 0.0001) at week 4 (vs. baseline). Assuming a 40-h workweek, tegaserod reduced work productivity loss by 2.5 h/week.
Conclusions : Tegaserod significantly reduced work productivity loss and daily activity impairment at 2 weeks, and this benefit was maintained at 4 weeks.